{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:53:29Z","timestamp":1767984809219,"version":"3.49.0"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2002,4,30]],"date-time":"2002-04-30T00:00:00Z","timestamp":1020124800000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Oral Pathology Medicine"],"published-print":{"date-parts":[[2002,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background:<\/jats:bold> Oral lichen planus (OLP) is a T cell\u2010mediated inflammatory disease. Interleukin\u20106 (IL\u20106) is a pro\u2010inflammatory cytokine that has effects on cellular and humoral immunities. Previous studies have shown that keratinocytes and tissue\u2010infiltrating mononuclear cells from OLP lesions can secrete IL\u20106. In some OLP patients, the high serum IL\u20106 levels are reduced after treatment, suggesting that IL\u20106 may be a useful marker in evaluating therapeutic effects and in monitoring the disease status of OLP.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> In this study, we used a solid phase, two\u2010site sequential chemiluminescent immunometric assay to determine the baseline serum levels of IL\u20106 in a group of 180 patients with erosive OLP (EOLP), nonerosive OLP (NEOLP), erythema multiforme (EM), traumatic ulcers (TU), oral submucous fibrosis (OSF), pemphigus vulgaris (PV), or Sj\u00f6gren's syndrome (SS), and in 77 normal control subjects. Some OLP patients were treated with levamisole plus Chinese medicinal herbs or levamisole only for 0.5\u20135.5\u2003months and their serum IL\u20106 levels were measured after treatment.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> We found that approximately 99% of the normal control subjects and the patients with EM, TU, or OSF had a normal serum IL\u20106 level less than 5.0\u2003pg\/ml. However, 15% (22\/149) OLP patients, 15% (20\/136) EOLP patients, 20% (5\/25) major type EOLP patients, 14% (15\/111) minor type EOLP patients, 15% (2\/13) NEOLP patients, 14% (1\/7) EM patients, 43% (3\/7) PV patients, and 100% (6\/6) SS patients had a serum IL\u20106 level greater than 5.0\u2003pg\/ml. The mean serum IL\u20106 level in patients with OLP (3.4\u2003\u00b1\u20033.1\u2003pg\/ml, <jats:italic>P<\/jats:italic> &lt;\u200a0.001), EOLP (3.4\u2003\u00b1\u20033.2\u2003pg\/ml, <jats:italic>P<\/jats:italic> &lt;\u200a0.001), major type EOLP (4.9\u2003\u00b1\u20033.5\u2003pg\/ml, <jats:italic>P<\/jats:italic> &lt;\u200a0.001), minor type EOLP (3.0\u2003\u00b1\u20033.0\u2003pg\/ml, <jats:italic>P<\/jats:italic> &lt;\u200a0.01), or NEOLP (4.2\u2003\u00b1\u20031.5\u2003pg\/ml, <jats:italic>P<\/jats:italic> &lt;\u200a0.001) was significantly higher than that in normal control subjects (2.0\u2003\u00b1\u20031.5\u2003pg\/ml). A significant difference in the mean serum IL\u20106 level was also found between major type and minor type EOLP patients (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01). The mean reduction of serum IL\u20106 level in OLP patients treated with levamisole plus Chinese medicinal herbs was significantly higher (7.4\u2003\u00b1\u20034.7\u2003pg\/ml) than that in OLP patients treated with levamisole only (3.8\u2003\u00b1\u20032.3\u2003pg\/ml, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05), suggesting that the combination therapy was superior to levamisole only.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> We conclude that levamisole and levamisole plus Chinese medicinal herbs can modulate the serum IL\u20106 level in OLP patients. IL\u20106 may be a useful marker in evaluating therapeutic effects and in monitoring the disease status of OLP.<\/jats:p>","DOI":"10.1034\/j.1600-0714.2002.310402.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T07:45:52Z","timestamp":1047455152000},"page":"196-203","source":"Crossref","is-referenced-by-count":52,"title":["Serum interleukin\u20106 level is a useful marker in evaluating therapeutic effects of levamisole and Chinese medicinal herbs on patients with oral lichen planus"],"prefix":"10.1111","volume":"31","author":[{"given":"Andy","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010San","family":"Chia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu\u2010Fong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun\u2010Pin","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,4,30]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1985.tb00516.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-2104(97)90244-4"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0344-0338(11)80226-8"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1990.tb00788.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00202068"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1995.tb32358.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830271140"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1996.tb01375.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1994.tb00067.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004030050442"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12606990"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(92)70138-6"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/89.3.329"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(94)90087-6"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1994.tb00250.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-2104(98)90370-5"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(98)01370-0"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19801115)46:10<2185::AID-CNCR2820461015>3.0.CO;2-5"},{"key":"e_1_2_5_20_2","first-page":"347","article-title":"The levamisole story","volume":"20","author":"Janssen PA","year":"1976","journal-title":"Prog Drug Res"},{"key":"e_1_2_5_21_2","first-page":"31","article-title":"Potentiation of interleukin\u20102 activity by levamisole and imidazole","volume":"4","author":"Redondo JM","year":"1978","journal-title":"Immunol Lett"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1994.tb01108.x"},{"key":"e_1_2_5_23_2","first-page":"815","volume-title":"Chinese Herbs.","author":"Hu HM","year":"1996"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0714.2001.300906.x"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1991.tb00927.x"},{"key":"e_1_2_5_26_2","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood.V76.10.1989.1989","article-title":"Cytokine regulation of colony stimulating factor production in cultured human synovial fibroblasts. I. Induction of GM\u2010CSF and G\u2010CSF production by interleukin\u20101 and tumor necrosis factor","volume":"76","author":"Leizer T","year":"1990","journal-title":"Blood"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0008-8749(89)90095-6"}],"container-title":["Journal of Oral Pathology &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0714.2002.310402.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0714.2002.310402.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0714.2002.310402.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T20:25:26Z","timestamp":1697574326000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0714.2002.310402.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["10.1034\/j.1600-0714.2002.310402.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0714.2002.310402.x","archive":["Portico"],"relation":{},"ISSN":["0904-2512","1600-0714"],"issn-type":[{"value":"0904-2512","type":"print"},{"value":"1600-0714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}